A prospective observational study conducted across two specialized treatment centers in Poland indicates that many individuals with cystic fibrosis who receive Cystic Fibrosis Transmembrane Conductance Regulator modulators can discontinue traditional maintenance therapies without experiencing major declines in respiratory or nutritional health.
These clinical improvements have prompted reconsideration of the need for traditional maintenance therapies, although reliable safety data remain limited.
To evaluate the safety and clinical consequences of altering these standard daily routines, investigators designed a prospective, dual-center observational protocol monitoring 138 individuals with cystic fibrosis. The participating patient cohort spanned an age range of 2 to 56 years, providing a broad demographic representation of both pediatric and adult individuals. The research team systematically stratified participants according to their chronological age, baseline lung function measurements, and whether they actively continued or discontinued specific maintenance therapies during the 12-month observation period.
Among the 138 participants enrolled in the cohort, a total of 61 patients, representing approximately 44 percent of the study population, chose to discontinue at least one maintenance therapy over the course of the year. The researchers observed distinct behavioral and therapeutic patterns in these treatment adjustments, noting that cessation occurred noticeably more often with inhaled agents than with oral formulations. Furthermore, the decision to stop maintenance therapy was recorded more frequently among adult participants who presented with preserved pulmonary function at the beginning of the study.
For the majority of patients monitored in the trial, stopping selected maintenance treatments did not lead to a measurable deterioration in overall respiratory function or nutritional status. General spirometric performance and body mass index scores remained comparable between those who discontinued therapies and those who sustained their daily maintenance regimens.
An important physiological exception emerged specifically among adult participants who chose to discontinue short-acting bronchodilator therapies. In this subgroup, oscillometry testing identified measurable deterioration in small airway function. In contrast, patients who continued short-acting bronchodilators maintained more favorable small airway values, demonstrating X10 +0.32 and AX -0.41 over the same evaluation period.
The study authors concluded that while many people with cystic fibrosis receiving CFTRm can discontinue maintenance therapies, especially inhaled medications, without encountering major functional harm, the observed changes in small airway function following bronchodilator withdrawal warrant careful scientific attention.
Subject of Research: Impact of CFTR modulator therapy on maintenance treatment discontinuation in cystic fibrosis
Article Title: Impact of CFTR modulator therapy on the use of maintenance treatment in patients with cystic fibrosis: a prospective dual-center study
Article References: Osińska, M., Narożna, B., Sapiejka, E., Famulska, P., Steinert-Dymecki, A., Olszewska, D., Tąpolska-Jóźwiak, K., Wiesner, A., Szczepankiewicz, A., Langwiński, W., & Wojsyk-Banaszak, I. (2026). Impact of CFTR modulator therapy on the use of maintenance treatment in patients with cystic fibrosis: a prospective dual-center study. BMC Pulmonary Medicine. https://doi.org/10.1186/s12890-026-04987-5
Image Credits: AI Generated
DOI: 10.1186/s12890-026-04987-5
Keywords: cystic fibrosis, CFTR modulators, maintenance therapy, spirometry, oscillometry, small airway function, bronchodilators, pulmonary medicine, prospective study, body mass index, lung function, inhaled therapies, oral therapies, Poland CF centers, observational study, respiratory parameters
News Source: Ophelia Keating. (November 12, 2026). Many Patients on CFTR Modulators Stop Maintenance Therapies Without Major Decline. Scienmag.



